Literature DB >> 20336622

Dopamine beta-hydroxylase-deficient mice have normal densities of D(2) dopamine receptors in the high-affinity state based on in vivo PET imaging and in vitro radioligand binding.

Mette Skinbjerg1, Nicholas Seneca, Jeih-San Liow, Jinsoo Hong, David Weinshenker, Victor W Pike, Christer Halldin, David R Sibley, Robert B Innis.   

Abstract

In vitro, D(2) dopamine receptors (DAR) can exist in low- and high-affinity states for agonists and increases of D(2) receptors in high-affinity state have been proposed to underlie DA receptor supersensitivity in vivo. Deletion of the gene for dopamine beta-hydroxylase (DBH) causes mice to become hypersensitive to the effects of psychostimulants, and in vitro radioligand binding results suggest an increased percentage of D(2) receptors in a high-affinity state. To determine whether DBH knockout mice display an increase of high-affinity state D(2) receptors in vivo, we scanned DBH knockout and control mice with the agonist PET radioligand [(11)C]MNPA, which is thought to bind preferentially to the high-affinity state of the D(2) receptor. In addition, we performed in vitro binding experiments on striatal homogenates with [(3)H]methylspiperone to measure B(max) values and the percentages of high- and low-affinity states of the D(2) receptor. We found that the in vivo striatal binding of [(11)C]MNPA was similar in DBH knockout mice and heterozygous controls and the in vitro B(max) values and percentages of D(2) receptors in the high-affinity state, were not significantly different between these two groups. In summary, our results suggest that DBH knockout mice have normal levels of D(2) receptors in the high-affinity state and that additional mechanisms contribute to their behavioral sensitivity to psychostimulants.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20336622      PMCID: PMC2894264          DOI: 10.1002/syn.20781

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  15 in total

1.  Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine.

Authors:  Jesse R Schank; Rossella Ventura; Stefano Puglisi-Allegra; Antonio Alcaro; Charlene D Cole; L Cameron Liles; Philip Seeman; David Weinshenker
Journal:  Neuropsychopharmacology       Date:  2005-12-14       Impact factor: 7.853

2.  Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain.

Authors:  Masanori Ichise; Jeih-San Liow; Jian-Qiang Lu; Akihiro Takano; Kendra Model; Hiroshi Toyama; Tetsuya Suhara; Kazutoshi Suzuki; Robert B Innis; Richard E Carson
Journal:  J Cereb Blood Flow Metab       Date:  2003-09       Impact factor: 6.200

3.  Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis.

Authors:  Philip Seeman; David Weinshenker; Remi Quirion; Lalit K Srivastava; Sanjeev K Bhardwaj; David K Grandy; Richard T Premont; Tatyana D Sotnikova; Patricia Boksa; Mufida El-Ghundi; Brian F O'dowd; Susan R George; Melissa L Perreault; Pekka T Männistö; Siobhan Robinson; Richard D Palmiter; Teresa Tallerico
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

4.  Restoration of norepinephrine and reversal of phenotypes in mice lacking dopamine beta-hydroxylase.

Authors:  S A Thomas; B T Marck; R D Palmiter; A M Matsumoto
Journal:  J Neurochem       Date:  1998-06       Impact factor: 5.372

5.  Anterior pituitary dopamine receptors. Demonstration of interconvertible high and low affinity states of the D-2 dopamine receptor.

Authors:  D R Sibley; A De Lean; I Creese
Journal:  J Biol Chem       Date:  1982-06-10       Impact factor: 5.157

6.  Mice with chronic norepinephrine deficiency resemble amphetamine-sensitized animals.

Authors:  David Weinshenker; Nicole S Miller; Katherine Blizinsky; Marc L Laughlin; Richard D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

7.  Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites.

Authors:  A Malmberg; E Jerning; N Mohell
Journal:  Eur J Pharmacol       Date:  1996-05-06       Impact factor: 4.432

8.  Specific binding of [(11)C]raclopride and N-[(3)H]propyl-norapomorphine to dopamine receptors in living mouse striatum: occupancy by endogenous dopamine and guanosine triphosphate-free G protein.

Authors:  Paul Cumming; Dean F Wong; Nicholas Gillings; John Hilton; Ursula Scheffel; Albert Gjedde
Journal:  J Cereb Blood Flow Metab       Date:  2002-05       Impact factor: 6.200

Review 9.  There and back again: a tale of norepinephrine and drug addiction.

Authors:  David Weinshenker; Jason P Schroeder
Journal:  Neuropsychopharmacology       Date:  2006-12-13       Impact factor: 7.853

10.  Ex vivo [11C]-(+)-PHNO binding is unchanged in animal models displaying increased high-affinity states of the D2 receptor in vitro.

Authors:  Patrick N McCormick; Shitij Kapur; Greg Reckless; Alan A Wilson
Journal:  Synapse       Date:  2009-11       Impact factor: 2.562

View more
  9 in total

1.  Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D₂ and D₃ Receptors.

Authors:  Maarten E A Reith; Aloke K Dutta; Dana E Selley; Juan Zhen; Tamara Antonio; Joanna C Jacob; David K Grandy
Journal:  Neurochem Res       Date:  2015-12-31       Impact factor: 3.996

Review 2.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

Review 3.  Imaging the high-affinity state of the dopamine D2 receptor in vivo: fact or fiction?

Authors:  Mette Skinbjerg; David R Sibley; Jonathan A Javitch; Anissa Abi-Dargham
Journal:  Biochem Pharmacol       Date:  2011-09-16       Impact factor: 5.858

4.  Chronic loss of noradrenergic tone produces β-arrestin2-mediated cocaine hypersensitivity and alters cellular D2 responses in the nucleus accumbens.

Authors:  Meriem Gaval-Cruz; Richard B Goertz; Daniel J Puttick; Dawn E Bowles; Rebecca C Meyer; Randy A Hall; Daijin Ko; Carlos A Paladini; David Weinshenker
Journal:  Addict Biol       Date:  2014-08-13       Impact factor: 4.280

5.  (-)-Stepholidine is a potent pan-dopamine receptor antagonist of both G protein- and β-arrestin-mediated signaling.

Authors:  Julie A Meade; R Benjamin Free; Nicole R Miller; Lani S Chun; Trevor B Doyle; Amy E Moritz; Jennie L Conroy; Val J Watts; David R Sibley
Journal:  Psychopharmacology (Berl)       Date:  2014-09-18       Impact factor: 4.530

6.  Pharmacogenetics of Dopamine β-Hydroxylase in cocaine dependence therapy with doxazosin.

Authors:  Xuefeng Zhang; David A Nielsen; Coreen B Domingo; Daryl I Shorter; Ellen M Nielsen; Thomas R Kosten
Journal:  Addict Biol       Date:  2018-03-02       Impact factor: 4.280

7.  Neurocognitive function in dopamine-β-hydroxylase deficiency.

Authors:  Marieke Jepma; Jaap Deinum; Christopher L Asplund; Serge Arb Rombouts; Jouke T Tamsma; Nathanja Tjeerdema; Michiel M Spapé; Emily M Garland; David Robertson; Jacques Wm Lenders; Sander Nieuwenhuis
Journal:  Neuropsychopharmacology       Date:  2011-04-06       Impact factor: 7.853

8.  Synthesis and evaluation in rats of homologous series of [(18)F]-labeled dopamine D 2/3 receptor agonists based on the 2-aminomethylchroman scaffold as potential PET tracers.

Authors:  Vladimir Shalgunov; Jan-Peter van Wieringen; Henk M Janssen; P Michel Fransen; Rudi A J O Dierckx; Martin C Michel; Jan Booij; Philip H Elsinga
Journal:  EJNMMI Res       Date:  2015-07-25       Impact factor: 3.138

Review 9.  Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging.

Authors:  Vladimir Shalgunov; Aren van Waarde; Jan Booij; Martin C Michel; Rudi A J O Dierckx; Philip H Elsinga
Journal:  Med Res Rev       Date:  2018-11-18       Impact factor: 12.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.